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Background: As originally proposed by Fries, conceptualizing morbidity solely through associated functional
limitation/disability (FL/D) remains the most widely accepted metric to assess whether increases in longevity
have been accompanied by a compression of morbidity.
Objective: To propose a departure from a highly restrictive FL/D-based definition of ‘‘morbidity’’ to a
broader view that considers the burden of chronic diseases even when no overt FL/D occur.
Design: We outline three reasons why the current framework of compression of morbidity should be
broadened to also consider morbidity to be present even when there are no overtly measurable FL/D. We
discuss various scenarios of morbidity compression and morbidity expansion under this broader rubric of
morbidity.
Conclusion: The rationale to go beyond a purely FL/D-based definition of morbidity includes: (1) substantial
damage from chronic disease that can develop prior to overt FL/D symptoms occurring; (2) multiple costs to
the individual and society that extend beyond FL/D, including medication costs, health care visits, and
opportunity costs of lifelong treatment; and (3) psychosocial and stress burden of being labeled as diseased
and the consequence for overall well-being. Adopting this broader definition of morbidity suggests that
increases in longevity have been possibly accompanied by an expansion of morbidity, in contrast to Fries’
original hypothesis that morbidity onset (based on only FL/D) would be delayed to a greater extent than
increases in survival. There is an urgent need for better data and more research to document morbidity onset
and its link with increases in longevity and assess the important question on whether populations while living
longer are also healthier.
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I
n 1980, James Fries proposed the concept of com-
pression of morbidity, which he defined as, ‘The
amount of [sic] disability can decrease as morbidity
is compressed intothe shorterspan betweentheincreasing
age at onset of disability and the fixed occurrence of
death ...Postponement of chronic illness thus results in
rectangularization not only of the mortality curve but
also of the morbidity curve’ (1, p. 133). In Fries’ view,
morbidity was represented by disability which resulted
from chronic illness: ‘Chronic illness now is responsible
for more than 80 per cent of all deaths and for an even
higher fraction of cases of total disability. Atherosclerosis
(including coronary-artery disease and stroke), arthritis,
adult onset of diabetes, chronic obstructive pulmonary
disease (including emphysema), cancer, and cirrhosis repre-
sent the overwhelming majorityofour health problems ...
Generally, they develop slowly and asymptomatically
below a clinical threshold, at which the process becomes
clinically evident, progresses, and often culminates in
death or disability. Disability and lowered quality of
life due to the most prevalent chronic diseases are thus
unescapably linked with eventual mortality’ (p. 132).
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chronic illness to have overtly measurable functional
limitation/disability (FL/D) in order to be considered
relevant.
The majority of the assessments on whether additional
years of life have been morbidity-free or not, conse-
quently, have relied solely on measuring the onset (or
levels) of FL/D over time to test whether there has been a
compression or expansion of morbidity, as opposed to
also considering the onset of the chronic disease them-
selves. There have been variants to this basic framework,
such as the dynamic equilibrium, (2) which posits that the
severity and progression of chronic disease would change
at the same pace as mortality improvements so that the
progression of disease would be stopped at early stages,
resulting in potentially more disease in the population
but disease with stable consequences in terms of FL/D.
However, any subsequent modifications to the basic idea
of Fries did not fundamentally alter the core tenet, that is,
morbidities are restricted to be impairment of individuals’
ability to perform certain functions [e.g. measured through
scales such as activities of daily living (ADL)] that could
result as a consequence of chronic disease.
In this comment, we develop an argument to not
restrict ‘morbidity’ simply to chronic illness with overtly
measurable FL/D but also include chronic disease even
if they do not lead to FL/D. We then summarize the
various scenarios of ‘compression’ and ‘expansion’ under
a broader rubric of morbidity definition. In what follows,
we use the term ‘disability compression’ to refer to changes
in FL/D indicators (incidence or prevalence) whereas
‘morbidity’ will be used to describe both disease and/or
FL/D related to disease. For instance, if a person has
diabetes but no FL/D, we would still consider them to
have morbidity. If they have diabetes and FL/D, they have
both morbidity and disability.
Before discussing morbidity compression more broadly,
we first consider the evidence for disability compres-
sion. Whether disability compression has occurred is
uncertain, in part due to available data, the FL/D mea-
sure employed, and the age range included in the different
studies. For instance, in the US, some research suggests
a small postponement in age at incidence from disability
[ADL and instrumental activities of daily living (IADL)]
between 1992 and 2003 for people aged 65 for severe
(people unable to complete at least three ADL’s) and
moderate (disabled in one or two ADL’s) disability, with
increasing rates of recovery from disability (3). How-
ever, a cross-survey comparison in five major studies in
the US shows that ADL disability prevalence had no
significant change from 1999/2000 to 2008 for people
aged 65 or older; although, one survey (the Health and
Retirement Study-HRS) shows a decline for people aged
85 or older in a 4-year period (20002004) while other
survey (Medicare Current Beneficiary Survey-MCBS)
suggests this decline had occurred for a longer period
(20002008) (4). Meanwhile, among younger adults (aged
5564) disability prevalence (ADL and IADL) has been
shown to be increasing over 20002004 (4); a result that
has also been reported for the rate of people needing help
with personal care activities at ages 5064 (5) and for
ADL disability for ages 4064 (6, 7). The latter results
indicate that incidence of disability is likely occurring
at earlier ages among younger adults; these are the same
cohorts that are experiencing high prevalence of health
risk factors such as obesity and dyslipidemia (8).
A rationale for going beyond disability-based
morbidity
Moving beyond a disability-based definition of morbidity
(i.e. considering an individual to have morbidity even
when they do not have FL/D) would entail considering
the broader array of chronic disease. A chronic disease
is a condition that can be controlled but not cured, in-
cluding metabolic derangements such as type 2 diabetes
and cognitive disorders such as Alzheimer’s disease. We
define as disease those chronic conditions that are in-
cluded in the International Classification of Diseases
(ICD-10) (9) such as hypertension, diabetes, obesity, and
mental and behavioral disorders (e.g. Alzheimer’s dis-
ease). These conditions not only increase the likelihood of
developing FL/D but also raise medical costs, result in
sub-clinical damage not measured through FL/D, and
have associated psychosocial and stress related burdens.
We outline three reasons why assessment on whether
increases in life expectancies have been accompanied by a
‘compression’ or ‘expansion’ of morbidity should con-
sider situations even when there is no overt FL/D.
First, substantial damage from chronic disease can
develop prior to overt symptoms occurring. For instance,
decline in kidney function from diabetes is largely
asymptomatic until function is severely impaired. Dia-
betes, hypertension, and dyslipidemia all will substan-
tially elevate risk of heart attack or stroke but the person
may be ‘symptom free’ until the actual event (e.g. heart
attack) occurs. The concept of ‘silent risk’ is captured in
risk scores, such as the Framingham Risk Score, that
recognize that even though no FL/D are occurring, the
presence of conditions such as dyslipidemia or hyperten-
sion are associated with considerable underlying physio-
logic damage (10).
Second, diseases are accompanied by multiple costs
to the individual and society that extend beyond FL/D,
and these costs may be expanding with earlier time of
diagnosis and longer duration of illness. Evidence sug-
gests that individuals with diseases such as diabetes are
not being diagnosed at an older age (11), rather, they are
experiencing a delay in the progression of the disease
where good control can be achieved through medical
therapy [which is consistent with the dynamic equilibrium
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transition: ‘the age of delayed degenerative diseases’ (12)].
But control of diseases such as diabetes and hypertension
are associated with medication costs, health care visits,
and opportunity costs, and most of these conditions re-
quire lifelong treatment. For example, in diabetic patients
there is evidence that achieving clinical treatment targets
(a lower value of HbA1c) may be associated with increas-
ing patient burden to the point of net harm, especially
among older adults (13). This reflects a potential trade-
off whereby improvement in clinical outcomes (and
reduction of some forms of diabetes related comorbidity)
may actually worsen overall quality of life.
Finally, diseases are also accompanied by social
stigma/psychosocial burden and stress of being labeled
as diseased. For example, in patients with a diagnosis
of diabetes, two major psychosocial themes that emerge
are anxiety and fear around complications of diabetes
with associated hopeless and depression, and work-
related discrimination and public misunderstanding around
diabetes (14). There is also evidence suggesting that psycho-
social burden and stress over long periods of time can
exacerbate disease consequences, the so-called allostatic
load (15, 16).
Alternative scenarios of morbidity compression
and expansion
We present different scenarios that could result from the
interplay of age of onset of morbidity (using the term
to comprehensively refer to both disease and/or FL/D
related to disease) and the increase in survival at older
ages Fig. 1. Examples are given relative to Fig. 1(A),
a baseline case in which morbidity onset occurs at age
X and death occurs at age Y. Figure 1(B) shows the
scenario posited by Fries whereby morbidity onset is
delayed to a greater extent than increases in survival.
However, three other scenarios all suggesting expansions
of morbidity are equally plausible: survival increases (i.e.
increasing average age at death) that are not accompanied
by delays in age at onset of morbidity (C), lesser delay in
age at onset of morbidity X relative to age at death Y (D),
and onset of morbidity occurring at earlier ages while
survival continues to increase (E).
We posit that scenario illustrated in Fig. 1(E) is highly
plausible. Although direct evidence on age at diagnosis
from nationally representative cohorts is not available,
indirect evidence on the health status of the adult US
population suggests morbidity expansion when the con-
cept of morbidity includes the broader array of chronic
Morbidity onset
Y (death) Birth
Morbidity expansion:
No change in morbidity
onset but survival increases 
Morbidity onset
Birth
Morbidity expansion:
Slower delays in morbidity
onset than increases in
survival
Y (death)
Morbidity onset
Birth
Morbidity expansion:
Earlier morbidity onset
and increases in survival
Morbidity onset
Y (death) Birth
Morbidity Compression:
Faster delays in morbidity
onset than increases in
survival
B)
C)
D)
E)
Morbidity onset
Y (death) Birth
A)
Baseline scenario:
Morbidity onset at age X and
death at age Y
X
Y (death)
Fig. 1. Models of compression/expansion of morbidity.
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gnosed diabetes more than doubled between 1995 and
2010 among people aged 1874 (11) and there was an
increase in the prevalence of adults who reported having
had a stroke or cancer between 1998 and 2006 (17).
Similarly, the prevalence of disease such as hypertension
in the adult US population appears to be on the rise. For
example, recent evidence from the National Health and
Nutrition Examination Survey (NHANES) indicates that
one-fifth of the adult population in 2010 (aged 20)
has at least three of the following: high glucose, high
triglycerides, low HDL-cholesterol, high waist circumfer-
ence, or high blood pressure (18); the prevalence of
overweight and obesity showed a continuous increase
in the 1990s among adults (aged 2074) with recent
increases in abdominal obesity (18), and the age-
standardized prevalence of hypertension increased be-
tween 19881994 and 20072010 among people older
than 20 years (11).
Among older adults (aged 65 or older) in the
US, there is also evidence of a rise in the incidence of
major chronic disease based on reconstructions of in-
dividual’s medical history from Medicare data (19). While
there was a decline in the incidence of some cardiovas-
cular events (e.g. angina pectoris and stroke) and some
cancers (e.g. colon and prostate) between 1992 and 2005,
there was also a rise in the incidence of diabetes, renal
disease, lung cancer, and Alzheimer’s disease.
These patterns have also been accompanied by inten-
sive use of medications. For example, the use of anti-
hypertensive and lipid modifying agents in the adult US
population significantly increased in the last decade (18).
These important sources of morbidity currently afflicting
the population are likely to lead to a potential scenario
whereby individuals would live longer  in part due to
improvements in case fatality rates from conditions such
as cardiovascular disease (CVD) as well as primary pre-
vention of CVD within individuals with diseases such
as hypertension and dyslipidemia  but with a higher
morbidity burden.
Compression versus expansion of morbidity:
future research
In this comment, we present a rationale for going beyond
the FL/D viewof morbidity to incorporate abroader view
thatconsiderssub-clinicaldamage,psychosocialandstress
burden, and increased cost associated with disease. This
broader view of morbidity simply brings back the basic
definition of this concept. As the epidemiologic profile of
populations change over time and our understanding and
ascertainment procedures about pathology improve, there
should also be a change in how we conceive and measure
morbidity. More than three decades have passed since
Fries proposed the frameworkof compression of morbid-
ity and advocated for FL/D as markers of morbidity; yet,
these indicators still dominate the assessment of this
framework. Although indirect evidence suggests morbid-
ity expansion rather than compression (as presented
above), there is an urgent need for systematic research to
documentmorbiditypatternsofmajorchronicdiseaseand
their link with increasing survival at older ages.
Many recent health surveys collect data on chronic
disease and underlying biomarkers of health allowing for
rich models to understand changes in morbidity patterns
and their link with mortality and survival at older ages (8,
20). Assessing whether compression of morbidity is truly
occurring would require representative data on incidence
of major chronic disease. Research on FL/D, for example,
has already pursued this endeavor by using comparable
FL/D measures with micro-simulation methods to infer
incidence and recovery from disability from nationally
representative surveys (either cross-sectional or long-
itudinal) (3, 21). Although some high-income countries
(e.g. OECD members) have survey data on FL/D to
assess disability compression, there is no data to assess
disease onset of major chronic disease in these countries.
In epidemiological and clinical research, there is no
nationally representative dataset in the US that allows
one to assess incidence of major chronic disease. For
example, major studies of cancer [e.g. the Surveillance,
Epidemiology, and End Results (SEER) nine registry
database] and heart disease (Framingham Heart Study)
keep records of incident events with consistent diagnostic
criteria for meaningful time trend analyses but are not
nationally representative. National health surveys (e.g.
NHANES) are cross-sectional in nature, limiting our
understanding of disease onset as these conditions slowly
develop over the individual’s life course and are often
undiagnosed. Nonetheless, major strides have been made
in recent years to overcome these data limitations by
reconstructing, under certain assumptions, individual’s
medical history from Medicare records to assess disease
onset (19, 22, 23). Operationalization of the broader
framework of morbidity that we propose will be challen-
ging. Although diagnosis of diseases such as diabetes,
hypertension or dyslipidemia is straightforward and well-
established criteria exist for each condition, capturing
and quantifying elements related to sub-clinical damage,
psychosocial burden and cost is more challenging. This
remains an important area for future research.
Discordance between mortality projections and
disease burden
A broader view of morbidity that considers the full im-
pact of chronic disease could have important implications
for public health policies. For instance, typical demo-
graphic and actuarial projections of mortality and life
expectancy rely on extrapolations of past trends in
demographic indicators with no attention paid to disease
epidemiology and how chronic disease is expanding over
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considering known health risk factors such as smoking
and obesity will lead the US Social Security Administra-
tion Trust Fund to run out 2 years earlier than the
government has predicted (24, 25). A broader morbidity
measure that includes chronic disease would suggest the
US Medicare Trust Fund would be exhausted even earlier
as medical costs associated with lifelong treatments are
likely to grow in the future.
An expanded view of morbidity has important implica-
tions to individuals, societies and governments. Chronic
diseases are not only accompanied by economic costs to
the individual resulting from earlier time of diagnosis and
lifelong treatments but they are also associated with
detrimental quality of life as a result of psychosocial and
stress burden. Major improvements in adult mortality in
the past decadeswill inevitably unfold as population aging
in the years to come with an increasing number of people
reaching older ages in most developed countries. It is
imperative to assess the health status of this growing
population. Societies and governments could face many
challenges if morbidity is expanding as age patterns of
publictransferstypicallyfavorolderadultssuggestingthat
national accounts would become even more unbalanced.
In summary, assessing compression of morbidity re-
quires a broader view on morbidity than just FL/D-based
indicators. If we want to assess the true impact of chronic
disease, we must consider impact across domains related
to FL/D, cost and psychosocial burden. This broader
conception is a better representation of the burden and
cost of illness to individuals and society and will allow for
improved estimates of the impact of the disease on health
care expenditure. This conception is an effort to more
realistically capture the impact of chronic disease when
assessing how a population is doing in terms of health.
More research needs to be done in this area with parti-
cular emphasis on evaluating the implications of a
broader view on morbidity for health care policies and
population projections. Such detailed cost-benefit assess-
ments accompanied by a broader view on morbidity need
to be part of the discussion on compression of morbidity.
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